-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: Leveraging Antibody-Drug Conjugates in Breast Cancer Care_Hope Rugo, MD, FASCO
53:15
-
Podium to Practice: Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting_Sara Hurvitz, MD, FACP_Sara Tolaney, MD, MPH
38:09
-
Sara Hurvitz, MD; University of California Los Angeles; 5Live #SABCS21
5:47
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Timothy Pluard, MD; St. Luke's Cancer Institute; 5Live #SABCS21
7:32
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Adam Brufsky, MD, PhD; University of Pittsburgh; 5Live #SABCS21
8:57
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Matthew Ellis, MB, BChir, PhD, FRCP; Baylor College of Medicine; 5Live #SABCS21
5:47
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Joanne Mortimer, MD; City of Hope: 5Live #SABCS21
5:20
Key insights from the 2021 Annual Breast meeting in San Antonio
-
Genomic assay in HR+/HER2- breast cancer; what we know and what we don't know_Kevin Kalinsky, MD, MS; #DDHO2021
4:29
-
Management of the axilla in breast cancer_Cletus Arciero, MD, FACS; #DDHO2021
2:04
-
Virginia Kaklamani, MD, DSc; UT Health San Antonio, MD Anderson Cancer Center; 5Live; #ASCO2021
5:04
-
Adam M. Brufsky, MD, PhD; UPMC Hillman Cancer Center University of Pittsburgh; 5Live; #ASCO2021
6:32
- Next Page
ABOUT
Bio Ascend is an independent medical education company committed to supporting healthcare providers in their efforts to translate innovative science into clinical practice.
The Bio Ascend team has deep oncology and hematology expertise with a proven ability to distill complex scientific ideas into their essential components, as well as extensive experience in planning, executing, and assessing meaningful education for clinicians.
CONNECT
© Copyright 2021 Bio Ascend, a Vaniam Group company